8-K: Glaukos Reports Record Q2 2026 Results, Raises Guidance

Glaukos Corporation announced record second quarter 2026 financial results, with net sales soaring 50% year-over-year to $185.6 million, prompting an increase in full-year revenue guidance.

Summary

• Glaukos Corporation reported record net sales of $185.6 million for the second quarter ended June 30, 2026, a 50% increase year-over-year (49% on a constant currency basis).
• Glaucoma net sales reached a record $155.2 million, up 50% year-over-year, with U.S. Glaucoma sales growing 64% to $118.5 million.
• Gross margin was approximately 82% (85% non-GAAP), and the company raised its full-year 2026 net sales guidance to $680 million $700 million, up from $620 million $635 million.
• The company reported a net loss of $18.4 million, or ($0.31) per diluted share, an improvement from a net loss of $19.7 million, or ($0.34) per diluted share, in the prior year's second quarter.
• Non-GAAP net loss was $8.3 million, or ($0.14) per diluted share, compared to a non-GAAP net loss of $13.6 million, or ($0.24) per diluted share, in Q2 2025.
• Cash and cash equivalents, short-term investments, and restricted cash totaled $289.3 million as of June 30, 2026, with no debt.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with record sales, raised guidance, and improved profitability metrics, indicating robust business momentum.

Positives

• Record net sales of $185.6 million in Q2 2026, a 50% year-over-year increase.
• Strong growth in Glaucoma net sales, reaching $155.2 million (up 50% YoY).
• Significant growth in U.S. Glaucoma sales, up 64% year-over-year to $118.5 million.
• Raised full-year 2026 net sales guidance to $680 million $700 million from $620 million $635 million.
• Improved gross margin to approximately 82% (85% non-GAAP).
• Reduced operating loss to $17.3 million from $22.7 million year-over-year.
• Reduced net loss to $18.4 million from $19.7 million year-over-year.
• Improved non-GAAP net loss to $8.3 million from $13.6 million year-over-year.

Negatives

• The company reported a net loss of $18.4 million for the quarter.
• Non-GAAP SG&A expenses increased 34% to $111.7 million.
• GAAP and non-GAAP R&D expenses increased 40% to $51.3 million.
• An acquired in-process R&D charge of $1.5 million impacted non-GAAP results.

Risks

• Potential risks include the ability to successfully commercialize iDose TR and Epioxa therapies.
• Macroeconomic conditions, foreign currency fluctuations, and public health crises could impact results.
• Supply and manufacturing disruptions, including product recalls or safety issues, are a concern.
• The company faces risks related to achieving or sustaining profitability and developing new products.
• International operations present inherent risks.
• Meeting customer expectations for product quality and delivery is critical.
• Potential for product misuse and the ability to manage growth and meet customer demand.
• Risks associated with acquisitions, collaborations, and partnerships.

Future Outlook

The company raised its full-year 2026 net sales guidance to a range of $680 million to $700 million, up from the previous guidance of $620 million to $635 million. This updated guidance considers potential contributions from iDose TR and Epioxa, potential headwinds during the third quarter related to the Photrexa to Epioxa transition, and uncertainties in the global macroeconomic environment.

Management Comments

• "Our record second quarter results reflect successful global execution across our key global commercial and development priorities, leaving us well positioned to sustain our strong growth momentum driven by two transformational growth drivers in iDose TR and Epioxa," said Thomas Burns, Glaukos chairman and chief executive officer.
• "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."

Industry Context

StockSavvy.ai notes that Glaukos' strong performance in Q2 2026, particularly in its glaucoma segment, aligns with the broader trend of increasing adoption of minimally invasive glaucoma surgery (MIGS) and novel drug delivery systems within the ophthalmology sector. The company's focus on innovative, dropless therapies positions it well against competitors.

Comparison to Industry Standards

• Glaukos' reported net sales growth of 50% year-over-year significantly outpaces the typical growth rates seen in the broader medical technology and pharmaceutical sectors, which often range from single digits to low double digits.
• The company's non-GAAP gross margin of approximately 85% is exceptionally high, indicating strong pricing power and efficient cost of goods sold, often exceeding industry averages for similar product categories.
• While Glaukos reported a net loss, the reduction in loss from operations and net loss year-over-year, coupled with increased revenue, suggests improving operational efficiency, a positive sign compared to companies struggling with revenue growth.
• The company's investment in R&D, representing approximately 27.6% of net sales in Q2 2026 ($51.3M / $185.6M), is substantial and indicative of a commitment to innovation, often higher than the average R&D spend in more mature segments of the healthcare industry.

Legal Proceedings

• Expenses related to trade secrets litigation and other litigation matters were $3.3 million in Q2 2026.

Stakeholder Impact

• Shareholders: Positive impact from increased revenue, raised guidance, and improved financial metrics, potentially leading to stock price appreciation.
• Patients: Continued access to innovative ophthalmic therapies like iDose TR and Epioxa, aimed at improving treatment outcomes for chronic eye diseases.
• Healthcare Providers: Introduction of new technologies like Epioxa, designed to streamline procedures and offer alternatives to traditional treatments.
• Payors: Ongoing efforts to secure market access and reimbursement pathways for new products like Epioxa.

Next Steps

• Continue advancing commercialization of iDose TR and Epioxa.
• Expand market access for Epioxa with payors.
• Advance clinical development programs for iDose TREX, iDose TRIO, and other pipeline assets.
• Monitor global macroeconomic and geopolitical environments.
• Prepare for the filing of the Q2 2026 Form 10-Q by August 10, 2026.

Key Dates

Recommendation

The company demonstrated exceptional top-line growth, significantly raised its full-year guidance, and showed improvement in profitability metrics. The successful commercialization of key products like iDose TR and Epioxa, coupled with a strong pipeline, indicates sustained growth potential, making it a compelling investment.

Keywords

ophthalmic, glaucoma, corneal disorders, retinal diseases, iDose TR, Epioxa, medical technology, pharmaceutical